ATE274057T1 - Spleissvarianten von lag-3 - Google Patents

Spleissvarianten von lag-3

Info

Publication number
ATE274057T1
ATE274057T1 AT98934908T AT98934908T ATE274057T1 AT E274057 T1 ATE274057 T1 AT E274057T1 AT 98934908 T AT98934908 T AT 98934908T AT 98934908 T AT98934908 T AT 98934908T AT E274057 T1 ATE274057 T1 AT E274057T1
Authority
AT
Austria
Prior art keywords
lag
nucleotidic
seq
code
sequences
Prior art date
Application number
AT98934908T
Other languages
English (en)
Inventor
Frederic Triebel
Renato Mastrangeli
Sergio Romagnani
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE274057T1 publication Critical patent/ATE274057T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Branch Pipes, Bends, And The Like (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
AT98934908T 1997-06-18 1998-06-03 Spleissvarianten von lag-3 ATE274057T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401404A EP0900841A1 (de) 1997-06-18 1997-06-18 Spleissvarianten von LAG-3
PCT/EP1998/003307 WO1998058059A1 (en) 1997-06-18 1998-06-03 Lag-3 splice variants

Publications (1)

Publication Number Publication Date
ATE274057T1 true ATE274057T1 (de) 2004-09-15

Family

ID=8229784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934908T ATE274057T1 (de) 1997-06-18 1998-06-03 Spleissvarianten von lag-3

Country Status (18)

Country Link
EP (2) EP0900841A1 (de)
JP (1) JP2002505582A (de)
KR (1) KR100552526B1 (de)
CN (1) CN1181201C (de)
AT (1) ATE274057T1 (de)
AU (1) AU740147B2 (de)
BR (1) BR9810925A (de)
CA (1) CA2293735A1 (de)
DE (1) DE69825741T2 (de)
DK (1) DK0977856T3 (de)
EA (1) EA003086B1 (de)
EE (1) EE04378B1 (de)
ES (1) ES2227862T3 (de)
HK (1) HK1027377A1 (de)
IL (2) IL133544A0 (de)
NO (1) NO996097L (de)
PT (1) PT977856E (de)
WO (1) WO1998058059A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100359A1 (en) * 2000-10-04 2003-05-29 Loose Timothy C. Audio network for gaming machines
EP1295895B1 (de) * 2001-09-19 2011-08-10 Institut Gustave Roussy An das Glu-Pro Motiv-bindende Proteine und Peptide, diese enthaltende therapeutische Zusammensetzungen und deren Anwendungen
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
EP2388265A1 (de) * 2002-02-22 2011-11-23 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
US7367886B2 (en) 2003-01-16 2008-05-06 Wms Gaming Inc. Gaming system with surround sound
US7867085B2 (en) 2003-01-16 2011-01-11 Wms Gaming Inc. Gaming machine environment having controlled audio and visual media presentation
US7364508B2 (en) 2003-01-16 2008-04-29 Wms Gaming, Inc. Gaming machine environment having controlled audio and visual media presentation
US8313374B2 (en) 2003-02-14 2012-11-20 Wms Gaming Inc. Gaming machine having improved audio control architecture
SI1897548T1 (sl) 2003-02-28 2013-12-31 The Johns Hopkins University Regulacija celic T
FR2902101B1 (fr) * 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
WO2008063391A2 (en) 2006-11-10 2008-05-29 Wms Gaming Inc. Wagering games using multi-level gaming structure
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US9412222B2 (en) 2013-09-20 2016-08-09 Igt Coordinated gaming machine attract via gaming machine cameras
HUE044730T2 (hu) 2013-09-20 2019-11-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
MX2018007406A (es) 2015-12-16 2018-08-15 Merck Sharp & Dohme Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
CA3136568A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0280710B1 (de) * 1986-08-21 1996-03-20 The Trustees Of Columbia University In The City Of New York Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
EP0758383B1 (de) * 1994-05-06 2007-01-24 Institut Gustave Roussy Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper

Also Published As

Publication number Publication date
EA003086B1 (ru) 2002-12-26
KR100552526B1 (ko) 2006-02-14
DE69825741T2 (de) 2005-09-01
NO996097L (no) 2000-02-17
ES2227862T3 (es) 2005-04-01
EP0977856B1 (de) 2004-08-18
EE9900581A (xx) 2000-08-15
IL133544A (en) 2006-12-31
CN1260833A (zh) 2000-07-19
EP0977856A1 (de) 2000-02-09
AU8435598A (en) 1999-01-04
KR20010013539A (ko) 2001-02-26
NO996097D0 (no) 1999-12-09
EP0900841A1 (de) 1999-03-10
EE04378B1 (xx) 2004-10-15
AU740147B2 (en) 2001-11-01
PT977856E (pt) 2005-01-31
DK0977856T3 (da) 2004-12-20
IL133544A0 (en) 2001-04-30
DE69825741D1 (de) 2004-09-23
CA2293735A1 (en) 1998-12-23
EA200000038A1 (ru) 2000-06-26
JP2002505582A (ja) 2002-02-19
CN1181201C (zh) 2004-12-22
HK1027377A1 (en) 2001-01-12
WO1998058059A1 (en) 1998-12-23
BR9810925A (pt) 2000-08-15

Similar Documents

Publication Publication Date Title
ATE274057T1 (de) Spleissvarianten von lag-3
AU7550098A (en) System for expressing hyperthermostable protein
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
DE69636495D1 (de) Multi-tumor abweichende wachstumsgene
ATE399858T1 (de) Blütenorgan-spezifische promotersequenzen
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
CY1106978T1 (el) Ενζυμα φωσφοδιεστερασης
DK0870833T3 (da) Gener for ultrathermostabile proteaser
NZ508439A (en) Novel endometriosis-associated gene
DE60015042D1 (de) Nukleotidsequenzen, welche für das dapF-Gen kodieren
ES2124694T3 (es) Clonacion de la n-metil-hidantoinasa.
HUP0001969A2 (hu) Az NNT-1 neurotróf faktor
ATE121456T1 (de) Klonierung und überexpression von glucose-6- phosphat-dehydrogenase aus leuconostoc dextranicus.
SE9801098D0 (sv) Receptors
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE180015T1 (de) N-carbamoylsarcosin-amidohydrolase, kloniert
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
DE69831584D1 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
DE60021707D1 (de) Beta-primeverosidase gen
WO1999060117A3 (fr) Polypeptide prax-1
TH14326A (th) โปรตีเอสและสารประกอบดีเอนเอที่เกี่ยวข้อง
TH19876A (th) จีนที่ประมวลรหัสและวิธีสำหรับแสดงลักษณะเอนไซม์ชนิดใหม่

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0977856

Country of ref document: EP

REN Ceased due to non-payment of the annual fee